Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Accured Expenses (2021 - 2025)

Aligos Therapeutics' Change in Accured Expenses history spans 5 years, with the latest figure at -$79000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 106.11% year-over-year to -$79000.0; the TTM value through Dec 2025 reached -$2.0 million, down 46.33%, while the annual FY2025 figure was -$2.0 million, 46.33% down from the prior year.
  • Change in Accured Expenses reached -$79000.0 in Q4 2025 per ALGS's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $9.9 million in Q4 2021 to a low of -$12.4 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$94950.0, with a median of $11500.0 recorded in 2021.
  • The largest YoY upside for Change in Accured Expenses was 89600.0% in 2022 against a maximum downside of 1242500.0% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $9.9 million in 2021, then plummeted by 75.76% to $2.4 million in 2022, then plummeted by 63.48% to $872000.0 in 2023, then surged by 48.28% to $1.3 million in 2024, then crashed by 106.11% to -$79000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Change in Accured Expenses are -$79000.0 (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).